Table 1.
Toxicity studies related to the use of adenoviral vectors.
| Analytical parameter | Reference range | Group I | Group II | Group III | |||
|---|---|---|---|---|---|---|---|
| Pre S | Post S | Pre S | Post S | Pre S | Post S | ||
| Leukocytes (μL) | 4000–12000 | 5507.5 ± 0.3 | 11086 ± 0.3 | 9748.3 ± 0.3 | 8375 ± 0.2 | 11251.7 ± 0.5 | 8758.3 ± 0.3 |
| Hemoglobin (g/dL) | 9–15 | 11.9 ± 0.2 | 9.72 ± 0.1 | 10.2 ± 0.2 | 10.3 ± 0.1 | 10.7 ± 0.1 | 10.1 ± 0.1 |
| Platelets (thousands/μL) | 220–680 | 376.2 ± 0.5 | 832.2 ± 0.3 | 470.3 ± 0.2 | 779.3 ± 0.4 | 684.1 ± 0.4 | 720.8 ± 0.5 |
| PT (g/dL) | 6.0–7.9 | 6.36 ± 0.1 | 6.68 ± 0.1 | 6.1 ± 0.0 | 7.1 ± 0.1 | 6.8 ± 0.1 | 6.8 ± 0.1 |
| Albumin (g/dL) | 2.4–3.0 | 3.46 ± 0.1 | 2.9 ± 0.1 | 3.1 ± 0.1 | 3.1 ± 0.1 | 3.1 ± 0.1 | 3.2 ± 0.1 |
| Globulin (g/dL) | 3.5–5.7 | 2.86 ± 0.1 | 3.76 ± 0.2 | 3.05 ± 0.1 | 4.2 ± 0.3 | 3.7 ± 0.2 | 3.5 ± 0.2 |
| AST (IU/L) | 66–194 | 146.4 ± 0.4 | 174.6 ± 0.3 | 131.5 ± 0.3 | 140.3 ± 0.6 | 112.1 ± 0.1 | 104.3 ± 0.2 |
| ALT (IU/L) | 12–37 | 17.8 ± 0.3 | 27 ± 0.9 | 19 ± 0.5 | 16.7 ± 0.3 | 15 ± 0.6 | 16.5 ± 0.4 |
| Total bilirubin (mg/dL) | 0.0–1.0 | 0.108 ± 0.4 | 0.032 ± 0.4 | 0.1 ± 0.6 | 0.04 ± 1.1 | 0.06 ± 0.6 | 0.04 ± 0.8 |
| Total bilirubin (mg/dL) | 0.0–0.2 | 0.03 ± 0.2 | 0.03 ± 0.4 | 0.1 ± 0.8 | 0.1 ± 1.2 | 0.04 ± 1.0 | 0.1 ± 0.7 |
| Indirect bilirubin (mg/dL) | 0.0–1.0 | 0.076 ± 0.6 | 0.03 ± 0.4 | 0.1 ± 0.8 | 0.1 ± 1.2 | 0.04 ± 1.0 | 0.1 ± 0.7 |
| Alkaline phosphatase (IU/L) | 68–387 | 305.8 ± 0.5 | 134.4 ± 0.2 | 167.5 ± 0.6 | 188.5 ± 0.3 | 198 ± 0.4 | 211.3 ± 0.3 |
| GGT (IU/L) | 36–102 | 53.8 ± 0.2 | 51.8 ± 0.1 | 68.2 ± 0.3 | 73.7 ± 0.3 | 49.07 ± 0.2 | 58.0 ± 0.4 |
Pre S: presurgery; Post S: postsurgery.